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Abstract
Introduction: We aimed to investigate the correlation between body composition
(BC) and spinal muscular atrophy (SMA)-specific motor function assessments.
Methods: Patients with SMA types I or II, aged 1 to 10 years, were recruited in this
cross-sectional study. The protocol included anthropometric measurements, and dual-
energy X-ray absoprtiometry to assess fat mass (FM), lean mass (LM), fat-free mass
(FFM), FM and FFM indexes (FMI, FFMI), and motor function assessments (Children's
Hospital of Philadelphia Infant Test of Neuromuscular Disorders scale for SMAI, and
Hammersmith Functional Motor Scale―Expanded for SMAII).
Results: Eighty-eight children were included. All had a higher FM percentage than
reference values. Motor function was moderately correlated with body mass
index (BMI), FFMI, and LMI in SMAI, and weakly correlated with FFMI, LMI, and
LM:FM ratio in SMAII.
Discussion: BC shows promise as a potential biomarker for SMA, but further studies
are needed.
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1 | INTRODUCTION
The approval and implementation of nusinersen as a treatment for
spinal muscular atrophy (SMA) in several countries has changed the
natural history of the disease by prolonging survival and improving
motor function.1,2 Other therapies are being developed, widening the
landscape of potential treatments for the near future. However, the
wide variability in the natural clinical course and that after treatment
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prompts the need to validate new biomarkers for future clinical trials,
and in the planning of patient-specific therapeutic programs.3
Dual-energy X-ray absorptiometry (DEXA) is the “gold standard”
to study body composition (BC)4 and is being used increasingly to
detect disease severity and monitor disease progression in neuromus-
cular disorders.5 The aim of the present study was to investigate the
correlation between BC and disease-specific motor function assess-
ments in SMA. Our hypothesis was that higher levels of residual mus-
cle bulk, as indicated by fat-free mass (FFM), are correlated with
higher motor function scores.
2 | METHODS
2.1 | Subjects and study design
Patients were recruited between April 2015 and May 2018 as part of
a large, ongoing, longitudinal, multicenter study on nutritional status
in SMA, according to the following inclusion criteria:
• Genetically confirmed diagnosis of 5q SMA types I or II.
• Age 1 to 10 years.
• Ability to perform DEXA scan and motor assessment.
• Absence of previous treatment with nusinersen or enrollment in a
clinical trial.
This study was approved by the ethics committees of the Univer-
sity of Milan and Carlo Besta Neurological Institute Foundation. All
parents signed informed consent before patient enrollment.
2.2 | Anthropometric measurements
Body weight (BW) and supine length (SL) were collected by the same
trained dieticians (R.D.A. andA.F.) according to a previously published stan-
dardized protocol,6,7 and bodymass index (BMI; kg/m2) was calculated.
Growth assessment was made using the 2000 US Centers for Dis-
ease Control and Prevention growth charts.8 BW and SL z-score values
below −1.645, corresponding to the <5th percentile, were considered
underweight and stunted, respectively. BMI z-score values below
−1.645 and above +1.645, corresponding to the <5th and > 95th per-
centiles, were considered wasted and obese, respectively.
2.3 | BC measurements
DEXA scans (iDXA; General Electric, formerly Lunar Corp, Madison, Wis-
consin) equipped with a pediatrics software application were used. The
FFM was calculated by adding bone mineral content (BMC) to lean mass
(LM). The FM percentage (FM%) was obtained as 100% × [total body fat
mass (g)] / [total body mass (fat mass + lean mass + bone mass of total
body) (g)]. Because total FM, FFM, and LM are related to body surface,
we also calculated FM (FMI; kg/m2), FFM (FFMI; kg/m2), and LM (LMI)
indexes by dividing total FM, FFM, and LM by height squared. The
FFM/FM ratio was also calculated. The total FM percentage of BW was
interpreted according to the BC of reference children9 calculating the
percentage of agreement between measured FM percentage with the
respective reference values for sex and age.
2.4 | Motor function assessment
Motor function was assessed by the Children's Hospital of Philadel-
phia Infant Test of Neuromuscular Disorders (CHOP INTEND) scale in
SMAI10 and the Hammersmith Functional Motor Scale―Expanded
(HFMSE) in SMAII children,11 performed by trained physiotherapists
(M.T.A. and R.Z.) who were blinded to anthropometric measurements.
2.5 | Statistical analysis
Discrete variables are reported as percentages. Continuous variables were
checked for normality. As most continuous variables had non-Gaussian
distributions, nondiscrete variables are reported as 25th, 50th, and 75th
percentiles. For the same reason, the Spearman correlation was used to
investigate the association ofmotor scales scoreswith the BC.We consid-
ered a correlation to be weak, moderate, or strong when the coefficient
was below 0.3, near 0.5, or approaching +1.0, respectively.12 P < .05 was
considered statistically significant. Statistical analysis was performed using
STATA version 12.0 (StataCorp, College Station, Texas).
3 | RESULTS
3.1 | Sample
Eighty-eight children (49 females, 39 males) were included in the analy-
sis, 43 with SMAI and 45 with SMAII (see Figure S1 online). Table S1
shows their characteristics. At the time of enrollment, the children were
receiving supportive care according to the recommendations of the Con-
sensus Statement for Standard of Care in SMA.13 Anthropometric mea-
surements, BC, and motor function scores are reported in Table 1.
3.2 | Nutritional status
SMAI and SMAII children showed median weight and height z scores,
respectively, lower and equal to the median values of standard of
growth charts. BMI z scores showed the children to be underweight,
especially those with SMAI.
3.3 | Body composition
All the children had a higher FM percentage compared with the
respective reference values for sex and age (median percentage of
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body fat above normal range: 16.7%; minimum 2.1%, maxi-
mum 45.0%).
3.4 | Motor function
Results for the SMAI and SMAII patients are presented in Table 1.
3.5 | Correlation between nutritional status, BC,
and motor function
The CHOP INTEND score in SMAI correlated moderately with BMI,
FFMI, and LMI (see Table S2 online, and Figure 1). Similarly, HFMSE
score in SMAII correlated weakly with FFMI, LMI, and LM:FM ratio,
but was not correlated with BMI (Figure 2).
TABLE 1 Anthropometric measurements, body composition, and motor function scores of study subjects
SMAI SMAII Total
P25 P50 P75 P25 P50 P75 P25 P50 P75
Age (months) 5 8 14 33 47 66 8 27 50
Anthropometric measurements
Weight (kg) 6.4 7.5 8.5 11.6 14.0 18.6 7.5 10.1 14.3
Weight (z score) −1.96 −1.21 −0.24 −2.11 −0.90 −0.22 −1.98 −1.04 −0.23
Length (cm) 66.5 72.0 79.0 91.0 100.0 117.5 72.3 89.5 102.0
Length (z score) −0.120 0.76 1.57 −1.410 −0.130 1.04 −0.840 0.34 1.50
BMI (kg/m2) 12.3 14.1 15.4 12.7 14.1 14.7 12.6 14.1 15.2
BMI (z score) −0.57 −1.99 −0.86 −2.52 −1.72 −0.52 −2.81 −1.76 −0.73
Body composition
Fat mass (kg) 2.4 2.6 3.4 3.7 4.7 7.6 2.6 3.6 5.0
Fat-mass index (kg/m2) 4.0 5.3 6.0 4.0 5.2 6.1 4.0 5.3 6.0
Fat-free mass (kg) 4.0 4.4 5.3 7.3 9.1 10.8 4.4 6.5 9.3
Fat-free mass index (kg/m2) 7.5 8.5 9.1 7.8 8.6 9.5 7.6 8.5 9.2
Lean mass (kg) 3.8 4.3 5.1 7.0 8.7 10.3 4.3 6.2 8.9
Lean mass index (kg/m2) 7.2 8.2 8.9 7.4 8.2 9.0 7.3 8.2 8.9
Lean:fat mass ratio 1.3 1.6 2.0 1.3 1.5 2.0 1.3 1.6 2.0
Motor function
CHOP INTEND score 17 29 42 ― ― ― 17 29 42
HFMSE score ― ― ― 6 10 16 6 10 16
Abbreviations: BMI, body mass index; CHOP INTEND, The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HFMSE,
Hammersmith Functional Motor Scale―Expanded; P25, 25th percentile; P50, 50th percentile; P75, 75th percentile.
F IGURE 1 Correlation between
nutritional status, body composition, and
CHOP scores
CHOP, The Children's Hospital of
Philadelphia Infant Test of Neuromuscular
Disorders score
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4 | DISCUSSION
In this study we have shown that FFM, and more specifically FFMI
and LMI, correlated with motor function in both SMAI and SMAII
patients, thus representing a potential biomarker for disease severity.
Despite advances in clinical and pharmacological management of
SMA patients, knowledge of their nutritional status and optimal nutri-
tional management remains limited. In our cohort, 44% of all patients
(54% of SMAI) were underweight (BMI z score less than −2), with only
1% (1 SMAII patient) overweight. FM was increased in both SMAI and
SMAII, showing increasing values with age. Previous studies by our
group and others have shown that FM is increased and FFM
decreased in SMA patients compared with healthy peers,6,14,15 and
that FFM and lean body mass are significantly lower in SMAI than
SMAII.6 Some authors have also reported that adiposity is increased
in nonambulatory, high-functioning SMAII compared with low-func-
tioning, and ambulatory patients.16 Due to this altered BC and the lack
of SMA-specific growth charts, regular assessment of BC by DEXA
has been included in the updated Standard of Care Recommendations
to ensure proper nutritional management.17
Sproule et al16 speculated that high FMI, as frequently observed
in SMAII patients, could negatively impact motor function. We did not
find any correlation between FMI and motor function in SMAII
patients, but LM:FM ratio (and not BMI, unlike in SMAI) correlated
with motor scores. This could be explained by the higher prevalence
of severely underweight SMAI children, whereas those with SMAII
had nutritional status that varied from under- to overnutrition, for
which management of BC rather than of weight is of primary
importance.
Our data show that motor abilities were weakly to moderately
correlated with FFMI and LMI in both SMAI and SMAII patients. This
is not surprising given that the degree of muscle atrophy and residual
muscle bulk, secondary to the underlying pathophysiology of the dis-
ease, likely play a major role in determining motor function in SMA
patients.
Although the regular assessment of BC is widely acknowledged
to be important in health maintenance and nutritional management of
children with SMA, it is rarely included in the routine follow-up
assessments. The main reasons for this are that DEXA is not always
available in clinical centers, and that other simpler techniques includ-
ing skinfold-based measures and predictive formulas are currently not
available for SMA. Another limitation to the implementation of the
use of DEXA in pediatric clinical trials is related to the (relatively small)
amount of radiation exposure.
The phase 3 studies of nusinersen have shown that some patients
respond well to treatment with acquisition of unexpected motor mile-
stones, whereas others have a more limited clinical response. The time
between the first symptoms and the first dose in patients with SMAI
and the age of those with SMAII have been reported to influence
response to treatment.1,2 However, these aspects cannot alone
explain the wide interindividual variability in response to treatment.
The high cost of orphan drugs may emerge as a limitation to
guaranteeing the worldwide accessibility of treatments to all SMA
patients,18 and the need to predict individual response or to identify
rules to stop or switch treatment to tailor therapy to patients will
increase over time. There is a strong need to identify informative clini-
cal and laboratory biomarkers that may allow monitoring of disease
progression and may predict responders. The role of DEXA as a sec-
ondary outcome measure to provide this information will require fur-
ther investigation.
In conclusion, this study has demonstrated that better BC is asso-
ciated with higher motor abilities in SMA patients. Our findings fur-
ther emphasize the importance of monitoring nutritional status in the
management of SMA patients. BC shows some promise as a potential
F IGURE 2 Correlation between
nutritional status, body composition and
HFMSE scores
HFMSE, Hammersmith Functional Motor
Scale―Expanded
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biomarker, but the strength of the correlations is not sufficiently uni-
form or consistent to yield immediate application. Further studies to
validate the assessment of BC as a biomarker for SMA, investigating
modifications in BC and motor function over time, and correlating BC
with clinical response to treatment will be performed in the near
future.
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